AI evidence summary · MVP
Melatonin for Gerd
AI preliminary evidence assessment
CC 級|AI 整體初步評級
This preliminary assessment is currently available in Traditional Chinese.
Exact question對確診胃食道逆流疾病的成人,在相同奧美拉唑治療下加用褪黑激素,是否改善逆流症狀或生活品質?
一項短期小型隨機試驗顯示,在相同奧美拉唑治療下加用舌下褪黑激素可能改善逆流症狀與生活品質;樣本數、四週追蹤與基線不平衡限制了確定性,且不能外推為褪黑激素單方效果。
Why this assessment was given
- 在相同奧美拉唑背景治療下,加用舌下褪黑激素4週後的胃食道逆流症狀頻率量表(FSSG)症狀分數較安慰劑低(10.02±2.43比14.97±3.28,P=.0001),胃食道逆流生活品質問卷(GERQ)生活品質分數較高(128.28±10.20比115.10±15.77,P=.0001);治療後心灼熱與上腹痛人數亦較少。這是加成效果,並非褪黑激素單方效果。
Limitations affecting this assessment
- 主要臨床結論來自單一四週、小樣本隨機試驗;78人隨機分派、72人納入最終分析,效益與安全性的精確度及長期適用性有限。
- 該試驗僅檢驗舌下褪黑激素3 mg加奧美拉唑20 mg,相較於奧美拉唑加安慰劑,不能外推為褪黑激素單方有效或可取代質子幫浦抑制劑。
- 隨機試驗兩組年齡有顯著基線不平衡,且以完成者分析;4名褪黑激素組及2名安慰劑組因不良反應或依從性不足被排除,可能造成偏差。
- 研究僅報告治療後組間差異及P值,未充分呈現調整後效果量、信賴區間或預先界定的臨床重要差異;生活品質量表亦含睡眠相關內容,可能放大褪黑激素的表觀效益。
- 2010年四組研究每個治療組僅9人,未清楚說明隨機分派或盲法,症狀並非以經驗證量表評估,因此只能作低可信度背景,不能補強主要臨床效果結論。
- 2010年研究所見酸鹼度、下食道括約肌及胃酸分泌變化屬輔助生理結果,不能取代經驗證的症狀或生活品質結果。
- 含褪黑激素、色胺酸、維生素及胺基酸的多成分補充品研究只有摘要資料,無法把效果歸因於褪黑激素,故不構成單方證據。
- 系統性回顧研究僅為計畫書而非結果,不能當成治療效果證據。
- 現有資料不足以可靠評估少見不良事件、停藥風險、復發、長期安全性及不同胃食道逆流疾病(GERD)表型的效果。
- 直接證據只有一項四週小型加成試驗;尚無可用的褪黑激素單方長期比較證據。
- 研究經費聲明明載未獲經費;L2 的 funding enum 因沒有 none 類別而保留 unknown,不能解讀為未報告或產業資助。
Research results
Findings are currently provided in Traditional Chinese; source excerpts retain their original language.
Main result 1
4 週在相同奧美拉唑背景治療下,加用舌下褪黑激素4週後的FSSG症狀分數較安慰劑低(10.02±2.43比14.97±3.28,P=.0001),GERQ生活品質分數較高(128.28±10.20比115.10±15.77,P=.0001);治療後心灼熱與上腹痛人數亦較少。這是加成效果,並非褪黑激素單方效果。
Applicability assessment: 相同奧美拉唑背景下的加成比較直接回答短期增量效果。
- Population
- 78名隨機分派的成人胃食道逆流疾病門診患者(72名完成)
- Intervention
- 舌下褪黑激素3 mg每晚加奧美拉唑20 mg每日
- Comparator
- 安慰劑每晚加相同奧美拉唑治療
- Outcome
- 胃食道逆流症狀頻率量表與生活品質
- Follow-up
- 4 週
- Formulation
- Not established
- Dose
- 舌下褪黑激素3 mg每晚
Source excerpt: The FSSG score was lower in the melatonin groupView source
Safety finding 2
4 週嗜睡為主要不良反應,褪黑激素組5例、安慰劑組3例;噁心、嘔吐、口乾及頭痛各自均少於3例,兩組整體不良反應差異無統計顯著性(P=.55)。
Applicability assessment: 同一隨機試驗直接比較短期不良反應。
- Population
- 78名隨機分派的成人胃食道逆流疾病門診患者(72名完成)
- Intervention
- 舌下褪黑激素3 mg每晚加奧美拉唑20 mg每日
- Comparator
- 安慰劑每晚加相同奧美拉唑治療
- Outcome
- 嗜睡與其他短期不良反應
- Follow-up
- 4 週
- Formulation
- Not established
- Dose
- 舌下褪黑激素3 mg每晚
Source excerpt: 5 cases in melatonin and 3 cases in placebo groupView source
Additional finding 3
2010年研究將健康對照與三個各9人的胃食道逆流治療組分開,未清楚說明隨機分派或盲法。
Applicability assessment: 小型研究且配置方法不清。
- Population
- 36名胃食道逆流患者與9名健康對照
- Intervention
- 褪黑激素、奧美拉唑或兩者合併
- Comparator
- 健康對照與不同治療組
- Outcome
- 症狀與生理指標背景
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Not established
Source excerpt: four groups: Group I included nine healthy normal subjects and was considered the control group.View source
Additional finding 4
此研究介入同時含褪黑激素、色胺酸、多種維生素、甲硫胺酸與甜菜鹼。
Applicability assessment: 多成分介入不可歸因。
- Population
- 有胃食道逆流症狀的成人
- Intervention
- 含褪黑激素的多成分補充品
- Comparator
- 奧美拉唑
- Outcome
- 症狀背景
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Not established
Source excerpt: a dietary supplementation containing: melatonin, l-tryptophan, vitamin B6, folic acid, vitamin B12, methionine and betaineView source
Additional finding 5
這篇文獻是預告將搜尋與評讀研究的系統性回顧計畫書。
Applicability assessment: 研究計畫書尚無結果。
- Population
- 計畫納入胃食道逆流患者
- Intervention
- 計畫評估褪黑激素或其受體促效劑
- Comparator
- 未使用褪黑激素的對照
- Outcome
- 規劃中的症狀改善結果
- Follow-up
- Not established
- Formulation
- Not established
- Dose
- Not established
Source excerpt: We will search the core databases [MEDLINE (through PubMed), the Cochrane Library, and Embase]View source
Sources consulted
- Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole. Context source; not counted as an included human-result report Abstract only · 2026-09-19T12:58:58.308742Z
- The potential therapeutic effect of melatonin in Gastro-Esophageal Reflux Disease. Context source; not counted as an included human-result report Full text · 2026-09-19T12:58:58.308742Z
- Melatonin for the treatment of gastroesophageal reflux disease; protocol for a systematic review and meta-analysis. Context source; not counted as an included human-result report Abstract only · 2026-09-19T12:58:58.308742Z
- Is the Addition of Sublingual Melatonin to Omeprazole Superior to Omeprazole Alone in the Management of Gastroesophageal Reflux Disease Symptoms: A Clinical Trial. Full text · 2026-09-19T12:58:58.308742Z
Reading and assessment notes
This is an AI preliminary assessment, not expert review or formal GRADE. Read the method and common limitations.
Absence of reported harms does not establish safety. This summary does not provide individual treatment or dosing advice.
Data and assessment record
Search coverage for this case
對確診胃食道逆流疾病的成人,在相同奧美拉唑治療下加用褪黑激素,是否改善逆流症狀或生活品質?
Searched:2026-09-19T12:58:58.308742Z · Databases:PubMed
35 records identified; 35 screened; 1 reports from 1 unique study populations included.
Some included reports were assessed without full text.
- 部分候選文獻未取得全文,完整偏倚風險與次要結果評讀受限。
- 本次檢索限於 PubMed 與已取得全文,未進行所有資料庫與完整引文追查。
Processing record
Evidence summary available
Sources through:2026-09-19 · Generated:2026-09-19T13:51:01.301510+00:00
Retrieved 35 records · Screened 35 · Included 1 reports · Omitted 34
Run:melatonin-gerd-verified-v8
codex_cli / gpt-5.6-sol / problem-search-source-bound-l2+l11-v1
{
"included": 1,
"limits_hit": [
"fulltext_unavailable",
"limited_citation_tracing"
],
"omitted": 34,
"retrieved": 35,
"screened": 35
} sha256:74ca2773ee87c1015fc5295cdf0f27286bad84dcf0e6a93d74b8635ffbc68761